166 related articles for article (PubMed ID: 11428057)
1. [Resistance to non-nucleoside reverse transcriptase inhibitors].
Casado JL; López JC; Viciana P
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):30-3. PubMed ID: 11428057
[No Abstract] [Full Text] [Related]
2. [Resistance to nucleoside reverse transcriptase inhibitors].
Leal M; Santamaría JM
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055
[No Abstract] [Full Text] [Related]
3. [Human immunodeficiency virus and antiretroviral therapy resistance].
Quirós E; Torti C; Carosi G
Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
[No Abstract] [Full Text] [Related]
4. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
5. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
6. Viral resistance: a major challenge in managing HIV disease.
Boucher CA; Reedijk M
J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
[No Abstract] [Full Text] [Related]
7. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
9. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
11. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
Moutschen M; Nkoghe D; Léonard P; Demonty J
Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
[No Abstract] [Full Text] [Related]
12. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
13. Evidence of dual sexual transmission of multi-resistant HIV with two years persistence of resistance to NRTI and NNRTI: a case report.
Zaccarelli M; Marconi P; Visco-Comandini U; Liuzzi G; Sette P; Acinapura R; Mosti S; Ammassari A; Perno CF; Antinori A
Infection; 2008 Mar; 36(2):178-80. PubMed ID: 17962906
[TBL] [Abstract][Full Text] [Related]
14. HIV resistance testing proves its value.
Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356
[TBL] [Abstract][Full Text] [Related]
15. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
[TBL] [Abstract][Full Text] [Related]
16. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
17. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
18. [Current situation of nucleoside reverse transcriptase inhibitors].
Ngo Van P
Ann Med Interne (Paris); 2000 Jun; 151(4):255-9. PubMed ID: 10922952
[TBL] [Abstract][Full Text] [Related]
19. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside reverse transcriptase inhibitors and HIV mutagenesis.
Jewell NA; Chen R; Raices R; Mansky LM
J Antimicrob Chemother; 2003 Oct; 52(4):547-50. PubMed ID: 12951341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
